NASDAQ · FBRX
Forte Biosciences, Inc.
$76.99$0.00 (0.0%)
Forte Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.27% below the high.
Loading market information…
NASDAQ · CRDF · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Cardiff Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.45% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Cardiff Oncology, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.14. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Cardiff Oncology, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:00 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 8, 2025 | -$0.20-5.26% vs estimate | $109.00K+22.07% vs estimate |
|---|
| Q4 2024 | Feb 27, 2025 | -$0.21+19.23% vs estimate | $151.00K+60.35% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | -$0.25+7.41% vs estimate | $165.00K+135.71% vs estimate |
|---|
KEEP COMPARING
$76.99$0.00 (0.0%)
Forte Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.27% below the high.
$2.41-$0.12 (-4.74%)
PepGen Inc.’s quoted price sits in the lower half of its reported 52-week range, 69.1% below the high.
$1.50-$0.02 (-1.32%)
Innate Pharma S.A.’s quoted price sits in the lower half of its reported 52-week range, 44.65% below the high.
$3.53-$0.18 (-4.88%)
Molecular Partners AG’s quoted price sits in the lower half of its reported 52-week range, 34.14% below the high.
$0.79+$0.03 (+4.25%)
Milestone Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.2% below the high.
$4.22-$0.03 (-0.71%)
Corbus Pharmaceuticals Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.52% below the high.
$1.32+$0.03 (+2.33%)
Cassava Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.49% below the high.
$0.61-$0.01 (-1.61%)
Rani Therapeutics Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 76.98% below the high.
THE ANALYST VIEW
15 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $2.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
